Workflow
低浓度阿托品
icon
Search documents
全国爱眼日:聚焦近视防控措施 有效降低近视风险
Ren Min Wang· 2025-05-29 01:51
谈到电子产品护眼功能,魏教授表示,虽然现代电子产品配备了一些护眼功能,但这并不能完全抵 消电子产品对眼睛的负担和近视形成的影响。因此,即使有护眼模式,也不能不加控制地长时间使用电 子产品。特别是对年龄小的婴幼儿,应禁止使用电子产品。对于幼儿园小朋友,要严格控制每天使用电 子产品的时间,小学生也不应超过一个小时。 魏文斌教授强调,通过科学用眼、增加户外活动、养成良好习惯和合理使用电子产品,可以有效降 低近视风险。另外,在医生指导下,采取综合防控措施,包括使用OK镜、低浓度阿托品点眼、功能性 眼镜以及改善阅读习惯等,可以帮助青少年控制近视进展或预防近视的发生。 6月6日是第30个全国"爱眼日",青少年近视防控一直是社会各界关注的热点话题。首都医科大学附 属北京同仁医院副院长、首批国家健康科普专家魏文斌教授就近视防控问题进行了深入科普,为家长和 孩子们提供了宝贵的指导。 魏文斌教授指出,青少年近视度数增长迅速,除了注意用眼习惯外,还有其他方法可以控制度数增 长。首先,要控制用眼时间,尤其是长时间、近距离的用眼时间。其次,增加户外活动,户外活动是眼 睛放松和防控近视最经济有效的措施之一。此外,养成良好的用眼习惯,包括 ...
兴齐眼药(300573):公司信息更新报告:业绩高速增长,2025年低浓度阿托品有望快速放量
KAIYUAN SECURITIES· 2025-04-30 07:25
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience rapid growth in 2025, particularly with the anticipated increase in sales of low-concentration atropine [3][4] - In 2024, the company reported a revenue of 1.943 billion yuan, representing a year-on-year increase of 32.42%, and a net profit attributable to shareholders of 338 million yuan, up 40.84% [3][4] - The company is positioned as a leader in the myopia prevention medication sector, with a strong focus on the promotion of its core product, low-concentration atropine [3][4] Financial Summary - The company's revenue is projected to grow from 1.943 billion yuan in 2024 to 2.948 billion yuan in 2025, reflecting a year-on-year growth rate of 51.7% [6] - The net profit attributable to shareholders is expected to increase significantly from 338 million yuan in 2024 to 688 million yuan in 2025, marking a growth of 103.6% [6] - The gross margin is forecasted to improve from 78.3% in 2024 to 80.6% in 2025, while the net margin is expected to rise from 17.4% to 23.3% during the same period [6] Product Development - The company has developed a series of ophthalmic products, including the first approved cyclosporine eye drops for dry eye syndrome in China, which generated sales of 298 million yuan in 2023 [4] - The approval of sulfate atropine eye drops in March 2024 is expected to enhance the company's product lineup and meet the growing demand for myopia treatment among children and adolescents [4] - The revenue from eye drops is projected to reach 1.366 billion yuan in 2024, with a remarkable growth rate of 106.08% [4]